Stock BRNS BARINTHUS BIOTHERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Barinthus Biotherapeutics plc

Equities

BRNS

US91864C1071

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.91 USD -4.50% Intraday chart for Barinthus Biotherapeutics plc -13.57% -48.24%
May. 13 Barinthus Biotherapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 01 Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective June 3, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
Barinthus Biotherapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective June 3, 2024
Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections
ADRs Advance; Connect Biopharma Climbs 19%
ADRs End Higher, Aesthetic Medical International Holdings Group Ltd. Climbs 35.5%
Barinthus Biotherapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
New partnership aims to advance vaccine against MERS coronavirus
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Barinthus Biotherapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BRNS Stock
  4. News Barinthus Biotherapeutics plc
  5. Other languages